Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Edit a Special Issue

Journal Menu

Journal Browser

► Journal Browser

Special Issue "Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers
Planned Papers

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 October 2023 | Viewed by 2708

Share This Special Issue

Special Issue Editor

Prof. Dr. Peter Stålberg
E-Mail Website
Guest Editor

Department of Surgery, Uppsala University Hospital, Uppsala University, Uppsala, Sweden
Interests: neuroendocrine tumors: diagnosis and treatment

Special Issue Information

Dear Colleagues,

This Special Issue focuses on the diagnosis and treatment of gastroenteropancreatic tumors, with world-leading experts in the field providing the readers with contemporary treatment and diagnosis algorithms, as well as a glimpse into novel and evolving treatments.

Gastrointestinal pancreatic neuroendocrine neoplasms (GEP-Nets) present many diagnostic and therapeutic challenges due to their relative rarity and complexity. Therefore, the latest findings on biomarkers, peptide receptor-based therapy or imaging therapy, etc., for the treatment of gastroenteropancreatic tumors are exciting. We would like to invite an array of scientific readers to contribute their research to this Special Issue of Cancers, dedicated to the generic topic of the diagnosis and treatment of gastroenteropancreatic tumors, such as gastric neuroendocrine tumors, pancreatic neuroendocrine tumors and small intestinal neuroendocrine tumors.

We would like to thank you in advance for your enthusiastic participation in this exciting Special Issue of Cancers.

Prof. Dr. Peter Stålberg
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

biomarkers
imaging
gastric NETs
pancreatic NETs
small intestinal NETs
receptor-based therapy

Published Papers (3 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle

Surgical Approach to Liver Metastases in GEP-NET in a Tertiary Reference Center

and

Cancers 2023, 15(7), 2048; https://doi.org/10.3390/cancers15072048 - 29 Mar 2023

Viewed by 589

Abstract

Indications for liver resection in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) vary from liver resection with curative intent to tumor debulking or tissue sampling for histopathological characterization. With increasing expertise, the number of minimally invasive liver surgeries (MILS) in GEP-NET patients has increased. However, the influence on the oncological outcome has hardly been described. The clinicopathological data of patients who underwent liver resection for hepatic metastases of GEP-NET at the Department of Surgery, Charité—Universitätsmedizin Berlin, were analyzed. Propensity score matching (PSM) was performed to compare MILS with open liver surgery (OLS). In total, 22 patients underwent liver surgery with curative intent, and 30 debulking surgeries were analyzed. Disease-free survival (DFS) was longer than progression-free survival (PFS) (10 vs. 24 months), whereas overall survival (OS) did not differ significantly (p = 0.588). Thirty-nine (75%) liver resections were performed as OLS, and thirteen (25%) as MILS. After PSM, a shorter length of hospital stay was found for the MILS group (14 vs. 10 d, p = 0.034), while neither DFS/PFS nor OS differed significantly. Both curative intended and cytoreductive resection of hepatic GEP-NET metastases achieved excellent outcomes. MILS led to a reduced length of hospital, while preserving a good oncological outcome. Full article

(This article belongs to the Special Issue Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms)

► Show Figures

Figure 1

Open AccessArticle

Prospective Multicentric Assessment of ⁶⁸Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET

Olivier-François Couturier

Rachida Lebtahi

François Rouzet

Philippe Ruszniewski

Françoise Kraeber-Bodéré

Mickaël Bourgeois

and

Catherine Ansquer

Cancers 2023, 15(2), 513; https://doi.org/10.3390/cancers15020513 - 14 Jan 2023

Cited by 1 | Viewed by 1095

Abstract

The aim of this multicentric study was to prospectively compare ⁶⁸Ga-DOTANOC PET/CT versus somatostatin receptor scintigraphy (SRS) with SPECT/CT, combined with multiphasic CT scan and MRI in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET). Patients with histologically proven grade 1 or 2 GEP-NET with suspicion of recurrence or progression, or with typical aspects of GEP-NET on morphological imaging, were explored with conventional imaging (CI): SRS with SPECT/CT, multiphasic CT scan and/or liver MRI followed by ⁶⁸Ga-DOTANOC PET/CT. The gold standard was based on histology and imaging follow-up. The data of 105 patients (45 woman and 60 men; median age) were analyzed. ⁶⁸Ga-DOTANOC PET/CT sensitivity was significantly higher than CI sensitivity in per-patient (98.9% vs. 88.6%, p = 0.016) and per-region (97.6% vs. 75.6%, p < 0.001) analyses, in the detection of the primary (97.9% vs. 78.7%; p = 0.016), peritoneal carcinomatosis (95% vs. 30%, p < 0.001), and bone metastases (100% vs. 33.3%, p = 0.041). ⁶⁸Ga-DOTANOC PET/CT had an impact on the therapeutic management of 41.9% (44/105) patients compared to decisions based on CI explorations. Our data confirm the superiority of ⁶⁸Ga-DOTANOC PET/CT over CI in the detection of peritoneal carcinomatosis and bone metastasis, as well as its strong therapeutic impact on the management of patients with grade 1-2 GEP-NETs. Full article

(This article belongs to the Special Issue Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms)

► Show Figures

Figure 1

Review

Jump to: Research

Open AccessReview

Surgical Management of Pancreatic Neuroendocrine Tumors

Megan L. Sulciner

and

Thomas E. Clancy

Cancers 2023, 15(7), 2006; https://doi.org/10.3390/cancers15072006 - 28 Mar 2023

Viewed by 626

Abstract

Pancreatic neuroendocrine tumors (PNETs) are relatively uncommon malignancies, characterized as either functional or nonfunctional secondary to their secretion of biologically active hormones. A wide range of clinical behavior can be seen, with the primary prognostic indicator being tumor grade as defined by the Ki67 proliferation index and mitotic index. Surgery is the primary treatment modality for PNETs. While functional PNETs should undergo resection for symptom control as well as potential curative intent, nonfunctional PNETs are increasingly managed nonoperatively. There is increasing data to suggest small, nonfunctional PNETs (less than 2 cm) are appropriate follow with nonoperative active surveillance. Evidence supports surgical management of metastatic disease if possible, and occasionally even surgical management of the primary tumor in the setting of widespread metastases. In this review, we highlight the evolving surgical management of local and metastatic PNETs. Full article

(This article belongs to the Special Issue Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms)

► Show Figures

Figure 1

Show export options Show export options

Select all

Export citation of selected articles as:

Displaying articles 1-3

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Neuroendocrine tumors of gastrointestinal tract, 57000 patients data, from SEER database
Authors: Asad Ullah; Nagla Abdel Karim
Affiliation: Department of Hematology and Oncology, Medical College of Georgia at Augusta University, Augusta, GA 30912

Title: Neuroendocrine tumors of gallbladder, 350 patients data from SEER database
Authors: Asad Ullah; Nagla Abdel Karim
Affiliation: Department of Hematology and Oncology, Medical College of Georgia at Augusta University, Augusta, GA 30912

Title: Gastrointestinal stromal tumor, 11000 patients data from SEER database
Authors: Asad Ullah; Nagla Abdel Karim
Affiliation: Department of Hematology and Oncology, Medical College of Georgia at Augusta University, Augusta, GA 30912

Journal Menu

Journal Browser

Special Issue "Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (3 papers)

Research

Review

Planned Papers

Further Information

Guidelines

MDPI Initiatives

Follow MDPI